For the fiscal year ending March 2026, J-Pharma Co.,Ltd. reported operating and ordinary losses, as well as a net loss of ¥2,842 million. The company forecast for the fiscal year ending March 2027 also indicates an outlook for losses.
J-Pharma Co.,Ltd.'s results for the fiscal year ending March 2026 were an operating loss of ¥2,841 million, an ordinary loss of ¥2,841 million and a net loss of ¥2,842 million. The summary figures from the income statement were published under Japanese accounting standards, with an update date of 24 June 2026.
The company forecast following the earnings announcement stated that operating profit for the fiscal year ending March 2027 was expected to be -¥2,841 million and net profit -¥2,842 million. The company's official forecast period is recorded as the fiscal year ending June 2026. These figures are based on official releases.
Some categories in the earnings information have missing data, and parts of the tables include data for the fiscal year ending month 0 of 0000, but the key loss figures are presented as actual results for the fiscal year ending March 2026 and the company forecast for the fiscal year ending March 2027.